Exelixis Results of Phase 3 Evaluating Cabozantinib in Advanced Neuroendocrine Tumors

 Cabozantinib continues to demonstrate a significant improvement in progression-free survival versus placebo in patients with advanced neuroendocrine tumors, including across key subgroups –

– Findings were the basis for the supplemental New Drug Application filed with the U.S. Food and Drug Administration for cabozantinib for advanced neuroendocrine tumors –

https://www.businesswire.com/news/home/20240913607414/en/